A comprehensive review of the bioregulator peptide targeting pineal gland function and CNS aging

Pinealon is a synthetic tripeptide—specifically, a three-amino-acid chain consisting of glutamic acid, aspartic acid, and arginine (commonly abbreviated as Glu-Asp-Arg or EDR)—developed in the 1990s as part of a broader research program into bioregulator peptides. Originating from the St. Petersburg Institute of Bioregulation and Gerontology under the direction of gerontologist Vladimir Khavinson, Pinealon joins a family of short peptides purported to exert selective effects on specific organs and tissues—in this case, the pineal gland and the central nervous system.

The premise underlying Pinealon’s development is straightforward enough: aging involves dysregulation of the pineal gland, which produces melatonin and other neurochemical signals critical to circadian rhythm, immune function, and cellular repair. If a short peptide could be engineered to restore pineal gland function—or to restore the expression of genes responsible for pineal output—it might slow or partially reverse certain aspects of central nervous system aging. The compound has accrued moderate interest in online longevity and self-experimentation communities, often used in combination with Epitalon and other peptide “stacks” aimed at systemic rejuvenation.

What makes Pinealon a critical case study for evidence-based longevity research is not what it may accomplish, but what it currently demonstrates: the gulf between preclinical promise and clinical proof. This article examines the mechanistic claims, the supporting laboratory and animal research, the complete absence of published human clinical trials, and the regulatory and safety landscape surrounding this compound. Our assessment will be direct: Pinealon is an interesting biological concept from a prolific research program, but it lacks the clinical validation necessary to support claims of human longevity benefit.

Table of Contents

• Quick Facts
• What Is Pinealon?
• Origins and Discovery
• Mechanism of Action
• Key Research Areas and Studies
• Common Claims versus Current Evidence
• The Human Evidence Landscape
• Safety, Risks, and Limitations
• Legal and Regulatory Status
• Research Protocols and Laboratory Practices
• Dosing in Published Research
• Dosing in Independent Self-Experimentation Communities
• Frequently Asked Questions
• Related Peptides: How Pinealon Compares
• Summary and Key Takeaways
• References and Key Studies
• Disclaimer

---

Quick Facts

↑ Back to contents

Compound	Pinealon (Glu-Asp-Arg tripeptide)
Type	Synthetic bioregulator peptide
Molecular Weight	~390 Da
Target Organ	Pineal gland; CNS tissue
Origin	St. Petersburg Institute of Bioregulation and Gerontology (Russia), ~1990s
Primary Developer	Vladimir N. Khavinson, PhD
Claimed Mechanisms	Melatonin synthesis upregulation; neuroprotection; gene expression modulation
Human Clinical Trials	None published in peer-reviewed Western medical literature
Evidence Tier	Preclinical only (cell culture, animal models)
WADA Status	Not listed; falls under S0 (general prohibition on peptides/hormones)
FDA Status	Not approved; not recognized as a drug
Storage Conditions	2–8°C (35–46°F), protected from light
Legal Status (USA)	Unregulated; sold as a research chemical or supplement; not for human consumption

---

What Is Pinealon?

↑ Back to contents

Pinealon is a tripeptide—a chain of exactly three amino acids—composed of glutamic acid (Glu or E), aspartic acid (Asp or D), and arginine (Arg or R), hence the designation EDR. At approximately 390 Daltons, it is a very small molecule, orders of magnitude smaller than most proteins or even larger peptides. This compactness is by design: Khavinson’s bioregulator peptide philosophy rests on the premise that short peptides, owing to their minimal size, can cross cell membranes directly and interact with intracellular targets—particularly DNA itself—to regulate gene expression without requiring the conventional receptor-mediated signaling pathways that govern larger hormones and proteins.

The name “Pinealon” reflects the intended tropism, or tissue selectivity, of the compound: it is theorized to accumulate in or preferentially affect the pineal gland, a pea-sized endocrine structure deep within the brain that synthesizes melatonin and participates in circadian regulation and immune modulation. Unlike Epitalon, which is similarly named for its presumed pineal and telomerase-targeting properties, Pinealon has not become a household name in mainstream aging research. Nevertheless, it occupies a niche in the peptide enthusiast and longevity research communities, particularly among individuals experimenting with multiple bioregulator peptides simultaneously.

From a chemical standpoint, Pinealon exists as a white to off-white lyophilized (freeze-dried) powder that must be reconstituted in sterile water or saline before use. It is poorly soluble in nonpolar solvents and does not cross the blood—brain barrier efficiently via oral administration, which is why research-grade material is typically administered via subcutaneous or intravenous injection, or occasionally via intranasal delivery in some experimental protocols.

---

Origins and Discovery

↑ Back to contents

Vladimir Nikolayevich Khavinson is a Russian gerontologist and biochemist with a prolific publication record spanning more than four decades. In the late 1980s and early 1990s, Khavinson and colleagues at what is now the St. Petersburg Institute of Bioregulation and Gerontology (formerly the Institute of Gerontology of the Academy of Sciences of the USSR) began synthesizing and testing short peptides extracted from or modeled after endogenous peptides found in various tissues. The theoretical foundation for this work was the observation that certain tissues, when ground into powder and administered orally or parenterally, appeared to confer some benefit to that same tissue in recipient animals—a phenomenon termed “protein-directed” or “tissue-specific” action.

This concept is not entirely novel: glandular extracts and organotherapies have a history spanning the late 19th and early 20th centuries, though the scientific validity of such approaches was largely abandoned in mainstream medicine. Khavinson’s innovation was to attempt to isolate and synthesize the active peptide components of these extracts, reasoning that short peptides (2–4 amino acids) might represent the smallest functional units and might be amenable to direct gene regulation at the DNA level—a proposal that deviates significantly from orthodox pharmacology and molecular biology.

Pinealon was among the peptides synthesized and evaluated in this program. Early work, conducted largely in Russian-language journals and conference proceedings, reported that Pinealon could enhance melatonin synthesis in pineal tissue, improve cognitive function in aged animals, and protect neurons against ischemic insult. The compound was patented in Russia and subsequently became available for research and, in some cases, for clinical use in Eastern European countries. Western interest in Pinealon remained minimal until the mid-2000s, when broader interest in “anti-aging” peptides and biohacking communities brought compounds like Epitalon (also from Khavinson’s lab) and subsequently Pinealon into greater visibility among self-experimenters.

It is important to note that Khavinson’s laboratory has produced dozens of such peptide candidates, each claimed to target specific organs or tissues: Thymalin (thymus), Vilon (spleen), Chelohart (cardiac tissue), Retinalamin (retina), and others. Pinealon occupies one position in this larger family. The fact that a research group has produced a substantial number of compounds that lack rigorous clinical validation does not necessarily discredit any single compound—but it does warrant skepticism toward extraordinary mechanistic claims made by that same group when clinical data are absent.

---

Mechanism of Action

↑ Back to contents

The Bioregulator Peptide Model

Khavinson’s theoretical framework posits that short peptides (2–4 amino acids) can penetrate cell membranes directly—bypassing receptor-mediated endocytosis or other conventional transport mechanisms—and interact directly with DNA in the nucleus. Once in the nucleus, these peptides are proposed to bind to specific DNA regions, interact with transcription factors, or act as cofactors for gene expression, thereby upregulating or downregulating the transcription of genes relevant to that tissue’s function and health.

This mechanism is fundamentally at odds with contemporary pharmacology and molecular biology. Small peptides, while more membrane-permeable than larger proteins, are still charged molecules at physiological pH and do not readily cross lipid bilayers without active transport or receptor-mediated uptake. Moreover, the specificity with which a tripeptide—composed of only three amino acids—could recognize and bind to a unique DNA sequence or interact with the correct transcription factors is implausible by current understanding. DNA recognition typically requires much larger proteins with multiple domains and specific three-dimensional structures that a tripeptide simply cannot provide.

Claimed Mechanisms for Pinealon

Within Khavinson’s framework, Pinealon is proposed to exert the following effects:

• Melatonin synthesis upregulation: Pinealon allegedly increases the expression of genes involved in melatonin biosynthesis (particularly aralkylamine N-acetyltransferase, AANAT, and hydroxyindole O-methyltransferase, HIOMT) in the pineal gland, thereby enhancing nocturnal melatonin production.
• Neuroprotection: Pinealon is claimed to reduce oxidative stress and apoptosis in neuronal cells, particularly under conditions of ischemia or excitotoxic insult, mediated by increased antioxidant gene expression or direct free-radical scavenging.
• Age-related cognitive preservation: Through restoration of pineal gland function and enhanced melatonin signaling, Pinealon is proposed to preserve cognitive performance, synaptic plasticity, and hippocampal function in aged organisms.
• Circadian rhythm stabilization: By restoring melatonin output, Pinealon may re-establish healthy circadian synchronization, thereby improving sleep quality and immune function.

These claims are theoretically coherent within the bioregulator model but remain unvalidated in human populations. The mechanism by which a three-amino-acid peptide achieves this specificity and potency remains unresolved.

---

Key Research Areas and Studies

↑ Back to contents

In Vitro Studies (Cell Culture)

Pinealon has been tested in cultured neuronal cell lines and pineal gland tissue explants. Representative studies report the following:

• Increased cell viability in cultured neurons exposed to glutamate excitotoxicity or oxidative stress, with Pinealon concentrations ranging from 10⁻⁹ to 10⁻⁶ M.
• Upregulation of antioxidant enzyme expression (SOD, catalase) in neuronal cultures, as assessed by real-time PCR or Western blotting.
• Enhanced melatonin production in cultured pineal gland tissue or pineal cell lines when incubated with Pinealon (10⁻¹⁰ to 10⁻⁸ M).
• Modulation of apoptotic gene expression (downregulation of pro-apoptotic markers such as caspase-3, Bax; upregulation of anti-apoptotic Bcl-2 family members) in neurons treated with Pinealon.

These results, while published in peer-reviewed journals (primarily Russian or Russian-language journals with limited Western circulation), demonstrate that Pinealon has some biological activity in cell culture. However, in vitro results do not reliably predict in vivo efficacy or safety in intact organisms, let alone in humans. Cells in culture are simplified models lacking the complexity of tissue architecture, vascular perfusion, immune cells, and neural circuits that characterize living brains.

Animal Studies (In Vivo)

Pinealon has been evaluated in rodent models, chiefly in rats and occasionally in mice. Key research areas include:

• Cognitive aging models: Aged rats (18–24 months old) treated with Pinealon (via subcutaneous or intraperitoneal injection, doses typically 0.1–1 mg/kg) showed improved performance on spatial memory tasks (Morris water maze, radial arm maze) compared to saline-treated controls. However, sample sizes in these studies are often small (n = 8–15 per group), and long-term follow-up is absent.
• Ischemic stroke models: In models of cerebral ischemia (transient or permanent middle cerebral artery occlusion), Pinealon administration (often given prior to or shortly after ischemia) reduced infarct volume and improved neurological outcomes as assessed by standardized scales. These studies provide evidence of acute neuroprotection but do not address whether chronic Pinealon use could prevent stroke or modify stroke risk in humans.
• Circadian rhythm assessment: Some studies report that Pinealon treatment in aged rats partially restores circadian rhythm amplitude and phase, as measured by activity monitoring and pineal melatonin secretion patterns.
• Oxidative stress markers: Tissue oxidative stress markers (malondialdehyde, protein carbonyls, lipid peroxides) are often reported to decrease in brain tissue from Pinealon-treated aged animals.

While these preclinical results are encouraging, they carry significant limitations. Rodent brains differ substantially from human brains in size, complexity, and aging phenotype. Dosing in animal studies is often not scaled appropriately for human translation. Most critically, the absence of pharmacokinetic data (tissue distribution, bioavailability, clearance) makes it impossible to infer what human doses would be necessary to achieve the same brain concentrations achieved in rats. Moreover, because Pinealon has never been administered to human subjects in a controlled clinical trial, we have no empirical basis to estimate whether the animal findings translate to humans at all.

---

Common Claims versus Current Evidence

↑ Back to contents

Claim	Current Evidence Status	Assessment
Pinealon restores melatonin synthesis in the aging pineal gland	Supported in aged rat models; not tested in humans	Preclinical evidence exists, but human validation is absent. Melatonin restoration in aged individuals is a plausible goal, but Pinealon’s efficacy in this regard is unproven in people.
Pinealon improves cognitive function and memory in aging	Supported in aged rat cognition models (Morris water maze, radial arm maze); no human trials	Rodent cognitive improvement is suggestive but does not establish efficacy in human aging or cognitive decline. Cognitive testing in humans requires longer-term studies and more sophisticated endpoints.
Pinealon protects the brain against stroke and ischemia	Supported in acute ischemia models in rats; no human stroke trials	Neuroprotection in acute ischemia is notable but does not address preventive or chronic use in humans. No data on human stroke outcomes or long-term safety.
Pinealon crosses the blood—brain barrier and enters neurons	Assumed in bioregulator model; not directly demonstrated in humans; limited pharmacokinetic data	Brain penetration is claimed but not empirically confirmed. Without pharmacokinetic data from humans, it is impossible to verify that Pinealon reaches the brain in concentrations sufficient to exert its claimed effects.
Pinealon binds to DNA and regulates gene expression	Claimed mechanistically; not demonstrated in vivo; inconsistent with established pharmacology	Direct DNA binding by a tripeptide is implausible by current molecular biology standards. No biochemical evidence (gel-shift assays, ChIP-seq, etc.) demonstrates this mechanism. Observed cellular effects could result from off-target mechanisms.
Pinealon is safe for human use	No long-term human safety data; no clinical trials; limited acute toxicology	Safety is unproven in humans. Absence of reported adverse events in research communities does not constitute safety evidence. Chronic off-target peptide effects, immunogenicity, and organ toxicity are not excluded.
Pinealon slows aging or extends lifespan	Not tested in any organism; lifespan data are absent	This is speculation. Even if Pinealon improves specific markers of aging (cognition, melatonin), this does not establish an effect on overall aging rate or lifespan. No animal lifespan studies have been published.

---

The Human Evidence Landscape

↑ Back to contents

To be unambiguous: there are no published, peer-reviewed clinical trials of Pinealon in humans in the Western medical literature. A search of PubMed, Web of Science, and Scopus for “Pinealon” OR “pineal peptide” OR “EDR peptide” combined with “human” OR “clinical” OR “trial” returns no results. There are no registered clinical trials on ClinicalTrials.gov or the WHO ICTRP (International Clinical Trials Registry Platform) for Pinealon.

There are claims, circulated in online biohacking and longevity communities, that Pinealon has been used clinically in Russia and is prescribed for age-related cognitive decline, sleep disturbance, and neuroprotection. However, these claims rest on anecdote and uncontrolled observation. No systematic data on efficacy, safety, or pharmacokinetics in human subjects have been published or made publicly available. Furthermore, the regulatory environment in Russia and other Eastern European countries differs substantially from that in the United States or European Union, meaning that compounds may be used clinically in those regions without the rigorous preclinical and early-phase human studies typically required in the West.

The absence of human clinical data is not a minor limitation—it is a foundational problem. Every drug, every supplement, every intervention with a claim to human benefit must eventually be tested in human subjects under controlled conditions, with appropriate measurement of relevant outcomes, accounting for placebo effects, natural history, and confounding factors. Until that work is completed, any claim about human efficacy is speculation.

Why No Human Trials?

One might reasonably ask why, if Pinealon has been developed and studied since the 1990s, no human clinical trials have been conducted and published. Possible explanations include:

• Regulatory barriers: Conducting clinical trials in the West requires IND (Investigational New Drug) applications to regulatory agencies and extensive preclinical safety work. This is costly and time-consuming. Khavinson’s laboratory may have lacked the resources or regulatory relationships to pursue this pathway.
• Scientific publication bias toward Western journals: Early clinical work, if conducted, may have been published in Russian-language journals with limited international circulation and indexing, making it difficult to identify via standard literature searches.
• Lack of commercial incentive: Peptides are not easily patentable as drugs (Pinealon is likely off-patent or difficult to enforce), and the global market for a single peptide is limited. A pharmaceutical company would need to invest $100+ million to conduct adequate clinical trials and gain regulatory approval—an investment that may not yield sufficient return for a niche compound.
• The compound may simply be insufficiently effective in humans: It is possible that effects observed in rodents do not translate to humans, or that they are trivial in magnitude, making human trials unlikely to succeed.

Regardless of the reason, the fact remains: we do not have human evidence of efficacy, safety, or optimal dosing for Pinealon.

---

Safety, Risks, and Limitations

↑ Back to contents

Lack of Formal Safety Data

Pinealon has not undergone formal toxicology studies in humans. The compound has undergone basic acute toxicity testing in rodents (LD₅₀ studies), which reportedly show low acute toxicity, but chronic toxicity data, teratogenicity studies, immunogenicity assessments, and drug—drug interaction studies have not been published or made publicly available for Pinealon.

Theoretical Safety Concerns

Short peptides can elicit immune responses, particularly if they are recognized as foreign by the adaptive immune system. Repeated parenteral administration could theoretically lead to antibody formation and neutralization of the peptide or cross-reactivity with self-peptides or proteins. This immunogenicity risk has not been systematically evaluated for Pinealon.

Unintended off-target effects are a concern for any bioactive molecule. Even if Pinealon does accumulate in the pineal gland (unproven), it could interact with non-target tissues or receptors, leading to unwanted effects. The narrow specificity claimed in the bioregulator model is theoretically implausible, raising the possibility of broader, unpredictable effects on the nervous system.

Melatonin signaling is complex and not uniformly beneficial across all tissues and contexts. Chronic elevation of melatonin synthesis could have unintended consequences on reproductive function, immune tolerance, or metabolic processes. These possibilities are entirely unexplored for Pinealon.

Purity and Contamination Risk

Pinealon obtained from research chemical suppliers and online vendors often lacks verified purity and sterility documentation. Contamination with endotoxins, other peptides, or synthetic residues is possible. Parenteral administration of impure material carries risk of pyrogenic reactions, allergic responses, or infection. Anyone considering use of such material should be aware that quality control may not meet pharmaceutical standards.

Individual Risk Factors

Pinealon is contraindicated (or should be used with extreme caution, if at all) in individuals with:

• Pineal gland pathology (cysts, tumors)
• Endocrine disorders, particularly those involving the pituitary—hypothalamic—gonadal axis
• Severe depression, bipolar disorder, or other psychiatric conditions sensitive to melatonin
• Immunocompromise or autoimmune disease
• Pregnancy or plans to become pregnant (no safety data)
• Concurrent use of other peptides or supplements with similar targets, due to additive risk

Self-Experimentation Risk

Online communities engaged in self-experimentation with Pinealon often do so without medical supervision, appropriate dosing guidance, baseline health assessment, or systematic monitoring for adverse effects. The risk of harm—whether from the peptide itself, from contaminants, or from interactions with other substances—is not negligible.

---

Legal and Regulatory Status

↑ Back to contents

FDA Status (United States)

Pinealon is not an FDA-approved drug. It is not recognized by the FDA as a food additive, generally recognized as safe (GRAS) substance, or dietary supplement ingredient. It is not approved for any indication. Under current U.S. law, peptides are generally subject to the Drug Approval Process (Investigational New Drug Application → Abbreviated New Drug Application or Biologics License Application) if marketed with disease claims. If marketed merely as a “research chemical” or “for research purposes only,” it operates in a regulatory gray zone where enforcement is inconsistent.

The FDA has authority to take action against sellers of Pinealon if it is marketed with health claims (e.g., “improves cognition,” “restores melatonin,” “reverses aging”), treating such marketing as an unapproved drug. To date, enforcement actions specifically targeting Pinealon have not been widely publicized, though the agency has taken action against other unapproved peptides and compounds sold in this manner.

WADA Status

The World Anti-Doping Agency (WADA) does not list Pinealon specifically on its Prohibited List. However, Pinealon falls under the class S0 (Non-Approved Substances, including peptide hormones, growth factors, and related substances), which is broadly prohibited in sport. Accordingly, any athlete subject to WADA rules should avoid Pinealon, as a positive test could result.

DEA Status

Pinealon is not a controlled substance under the Controlled Substances Act. It does not fall into any schedule that would impose federal criminal penalties for possession or distribution.

International Status

Pinealon is used clinically in some Eastern European countries, particularly Russia and Belarus, where it may be prescribed or available via clinical research programs. The regulatory approval process in these jurisdictions differs substantially from FDA requirements and may not involve the same rigor of safety and efficacy evaluation. In the European Union, peptides are subject to pharmaceutical regulations, and Pinealon would require marketing authorization; to our knowledge, no such authorization has been granted for Pinealon in the EU.

Vendor and Supply Issues

Pinealon is sold by online research chemical vendors under disclaimers that it is “for research purposes only” and “not for human consumption.” These disclaimers are often used as legal protection against drug sale regulations, regardless of the vendor’s actual knowledge of whether purchasers intend to use the compound on themselves. The legal status of purchasing, possessing, and self-administering Pinealon in the United States is ambiguous—it is likely not illegal for personal possession, but distribution with health claims would constitute drug trafficking.

---

Research Protocols and Laboratory Practices

↑ Back to contents

In Vitro Protocol Overview

Pinealon in cell culture studies is typically applied at concentrations ranging from 10⁻¹² M to 10⁻⁶ M, dissolved in culture medium or in PBS (phosphate-buffered saline). Neuronal cell lines used include primary rat cortical neurons, immortalized lines (e.g., SH-SY5Y neuroblastoma cells), and hippocampal slice cultures. Pineal gland tissue, either freshly isolated or cultured, is also employed. Endpoints measured include:

• Cell viability (MTT assay, LDH release, flow cytometry with live/dead staining)
• Oxidative stress markers (ROS, glutathione, malondialdehyde)
• Gene expression (qPCR for antioxidant genes, pro-apoptotic/anti-apoptotic genes, melatonin synthesis genes)
• Protein expression (Western blotting, immunofluorescence)
• Apoptosis/necrosis (TUNEL, annexin V staining, caspase assays)

Incubation periods are typically 24–72 hours. Controls include vehicle-only wells and positive controls (e.g., antioxidants, melatonin itself) to validate assay performance.

Animal Protocol Overview

In rodent studies, Pinealon is administered to aged rats (18–24 months, equivalent to ~60–70 years in humans) or young adult rats (3–4 months, ~25 years equivalent). Dosing routes include:

• Subcutaneous (s.c.) injection: Most common; doses 0.1–1 mg/kg administered once daily or every few days for 2–4 weeks
• Intraperitoneal (i.p.) injection: Doses 0.5–2 mg/kg; less commonly used
• Intranasal administration: Doses 0.1–0.5 mg/kg; some studies propose this to enhance CNS penetration

Typical study duration is 2–6 weeks. Behavioral endpoints include Morris water maze (spatial memory), radial arm maze (working/reference memory), grip strength, and open field activity (general locomotion and anxiety-like behavior). Tissue endpoints include histological assessment of infarct size (in stroke models), immunohistochemistry for marker proteins, and biochemical measurement of oxidative stress markers in brain homogenates.

Pharmacokinetics (Not Adequately Studied)

Notably, pharmacokinetic studies of Pinealon in rodents or humans—measuring tissue distribution, brain penetration, bioavailability, half-life, and metabolism—have not been published. This is a substantial gap. Without PK data, it is impossible to:

• Confirm that Pinealon reaches the pineal gland or brain tissue
• Establish appropriate human doses based on animal data
• Assess whether peripheral Pinealon interacts with non-target tissues
• Understand the duration and time course of action

The absence of PK data severely constrains the translation of animal results to human application.

---

Dosing in Published Research

↑ Back to contents

Study Type	Route	Dose (mg/kg)	Frequency	Duration	Model/Subject
In vitro	N/A (media concentration)	10−12–10−6 M	Single addition	24–72 hours	Neuronal cell lines, primary neurons, pineal tissue
Aged rat cognition	s.c. injection	0.1–0.5	Once daily	14–28 days	20–22 month old Wistar or Sprague-Dawley rats
Cerebral ischemia (stroke model)	s.c. or i.p. injection	0.5–1.0	Once daily, often starting 1 day pre-ischemia	3–7 days pre- and 7–21 days post-ischemia	Adult male Wistar or Sprague-Dawley rats
Neuroprotection (excitotoxicity)	i.p. injection	1.0–2.0	Single or repeated doses	1–3 days	Young adult rats
Intranasal	Intranasal administration	0.1–0.5 (volume/animal)	Once or twice daily	7–28 days	Aged rats

Key observations:

• In vitro concentrations span a wide range (10⁻¹²–10⁻⁶ M), with effects observed at concentrations as low as 10⁻¹² M, which is remarkably potent if reproducible. However, the biological relevance of such low concentrations is unclear.
• Animal dosing is typically in the range 0.1–1 mg/kg, which translates (using standard allometric scaling of 6–10× reduction for humans) to approximately 0.01–0.1 mg/kg in humans—or roughly 0.7–7 mg for a 70 kg adult. This is speculative without pharmacokinetic data.
• Study durations are relatively short (2–4 weeks), and long-term dosing effects are not well characterized.

---

Dosing in Independent Self-Experimentation Communities

↑ Back to contents

Route	Dose (Community Reports)	Frequency	Duration	Reported Rationale
Subcutaneous injection	1–5 mg per injection	Once daily or 3–5× per week	4 weeks–3 months per “cycle”	Mimics animal study dosing scaled informally to human body weight; believed to be safe based on lack of reported acute toxicity in animal studies
Intranasal spray/solution	0.5–2 mg per nostril, once or twice daily	Daily	2–4 weeks	Claimed to enhance CNS penetration; avoids injection; perceived as safer or more tolerable
Oral (rare)	5–50 mg once or twice daily	Daily	2–8 weeks	Used despite low bioavailability expectations; some reports claim oral bioavailability via enteric coating or mucoadhesive formulations
Stacked with other peptides	Pinealon 1–5 mg + Epitalon 0.5–2 mg + others (Thymalin, DSIP)	Daily or 3–5× weekly	4–12 weeks	Synergistic anti-aging effects hypothesized; no evidence for synergy; increases risk due to multiple unproven compounds

Community dosing practices are highly variable and lack scientific basis. Self-experimenters typically infer dosing from:

• Informal scaling of animal study doses to human body weight
• Vendor guidance, which varies widely and is not evidence-based
• Anecdotal reports from others in online forums
• Trial-and-error adjustment based on subjective perceived effects

None of these approaches is scientifically rigorous. Optimal human dosing remains unknown. Self-experimenters also frequently combine Pinealon with other peptides, supplements, and drugs, creating a complex and uncontrolled polypharmacy scenario with no systematic assessment of safety or interactions.

---

Frequently Asked Questions

↑ Back to contents

1. Is Pinealon the same as melatonin?

No. Melatonin is a small-molecule hormone synthesized by the pineal gland from the amino acid tryptophan. Pinealon is a synthetic peptide (three amino acids) claimed to enhance melatonin production. They are distinct compounds with different structures and mechanisms. Pinealon is not a form of melatonin and should not be used as a melatonin substitute.

2. Can Pinealon be taken orally?

Pinealon is a peptide and will be broken down by stomach acid and digestive enzymes if swallowed. Oral bioavailability is expected to be negligible unless the peptide is in a specially designed formulation (enteric-coated, liposomal, etc.), but such formulations are not standard in research chemical vendors. Some self-experimenters report using oral Pinealon, but there is no evidence that oral dosing achieves therapeutic effects. Subcutaneous or intranasal administration is more likely to reach the nervous system.

3. How does Pinealon compare to Epitalon?

Both are synthetic bioregulator peptides from Khavinson’s laboratory. Epitalon (AEDG, a tetrapeptide) is theorized to target the pineal gland and activate telomerase. Pinealon (EDR, a tripeptide) is a more recent compound also targeting the pineal gland but with emphasis on melatonin synthesis and neuroprotection. Neither has been tested in humans. Epitalon has somewhat more published research (especially in Russian journals) and is more widely discussed in longevity communities. The relative potency or superiority of one over the other is unknown.

4. Is Pinealon approved by any regulatory agency?

No. Pinealon is not FDA-approved in the United States, not approved in the European Union, and not recognized as a drug or dietary supplement ingredient in Western regulatory frameworks. It may be prescribed or used clinically in Russia and some Eastern European countries, but this does not constitute Western regulatory approval.

5. What are the side effects of Pinealon?

There are no published systematic studies of Pinealon side effects in humans. Theoretical risks include immunogenicity (antibody formation), disruption of melatonin signaling with unintended consequences on sleep, mood, reproduction, or metabolism, and off-target effects on non-pineal tissues. Practical risks include infection or pyrogenic reactions from contaminated material, and interactions with other drugs or supplements. Anecdotal reports from self-experimenters describe occasional headaches, sleep disturbance, or mood changes, but these are not systematically documented and may reflect placebo, nocebo, or confounding.

6. Can Pinealon extend human lifespan?

There is no evidence that Pinealon extends lifespan in any organism. Even if Pinealon improved specific aging-related markers (cognition, melatonin synthesis), this would not constitute evidence for lifespan extension. Lifespan is the ultimate test of any anti-aging intervention, and no animal lifespan studies of Pinealon have been published. Claims that Pinealon “slows aging” or “extends lifespan” are speculation.

7. Where can I buy Pinealon, and is it safe to buy from online vendors?

Pinealon is sold by online research chemical suppliers. These vendors typically disclaim that the product is “for research purposes only” and “not for human consumption.” The safety of purchasing from such vendors is limited. Purity, sterility, and identity are often not verified by independent testing. Contamination is possible. Vial contents may not match labels. Furthermore, purchasing with intent to self-administer may expose you to legal risk, though enforcement is inconsistent. If you are considering use, seek guidance from a healthcare provider who is familiar with peptides and willing to supervise use responsibly.

---

Related Peptides: How Pinealon Compares

↑ Back to contents

Pinealon versus Epitalon

Epitalon (Ala-Glu-Asp-Gly, AEDG) is a tetrapeptide (four amino acids) from the same research program. It is claimed to activate telomerase, extend telomeres, and restore pineal gland function. Epitalon has a larger publication record than Pinealon, with more studies in rodent models and some anecdotal clinical use. However, like Pinealon, Epitalon lacks published human clinical trials. The theorized mechanisms—direct telomerase activation and organ-specific gene expression modulation—are both implausible by conventional pharmacology standards. Epitalon has greater name recognition in the longevity community, but this reflects marketing visibility rather than superior scientific evidence. Neither compound has proven efficacy in humans.

Pinealon versus Thymalin

Thymalin is a polypeptide extract (or synthesized analog) from thymic tissue, also from Khavinson’s group, claimed to target the thymus and immune function. Thymalin is somewhat older (developed earlier) and has been used clinically in Russia and Eastern Europe for decades. It is not FDA-approved but has been imported and used in some U.S. clinical contexts off-label. Thymalin is larger and more complex than Pinealon, and the immunological argument for thymic targeting is more plausible (the thymus is an immune organ). However, evidence of efficacy in humans remains limited, and long-term randomized controlled trials are lacking. Thymalin and Pinealon are often used together in “immune + CNS” anti-aging stacks, but synergy is not established and may not exist.

Pinealon versus DSIP (Delta-Sleep-Inducing Peptide)

DSIP (a nonapeptide, nine amino acids) is a naturally occurring peptide discovered in the 1970s in cerebral spinal fluid and associated with sleep promotion. DSIP is from a different source (not Khavinson’s group) and has received slightly more research attention in sleep and circadian rhythm literature. Some studies suggest DSIP may improve sleep quality and have anxiolytic properties, though the evidence is weak and human trials are minimal. DSIP is less commonly used in self-experimentation than Epitalon or Pinealon, but appears occasionally in peptide stacks. The mechanistic plausibility of DSIP (enhancing sleep via natural sleep peptide) is higher than the gene-regulation claims of Pinealon, but evidence remains insufficient.

Comparison Table

Peptide	Structure	Target Organ	Claimed Mechanism	Publication Volume	Human Trials Published	Clinical Use (Eastern Europe)
Pinealon	Tripeptide (Glu-Asp-Arg)	Pineal gland, CNS	Melatonin synthesis, neuroprotection	Low	None	Limited
Epitalon	Tetrapeptide (Ala-Glu-Asp-Gly)	Pineal gland, telomeres	Telomerase activation, pineal restoration	Moderate	None	Limited
Thymalin	Polypeptide (variable, ~4 kDa)	Thymus, immune	Immune restoration, T-cell function	Moderate	Few, limited quality	Established
DSIP	Nonapeptide (9 amino acids)	Brain, sleep centers	Sleep promotion, circadian regulation	Moderate	Few, limited quality	Limited

Summary: All four peptides lack adequate human clinical evidence. None is FDA-approved. Pinealon ranks lowest in publication volume and has the least evidence base, even compared to other Khavinson-derived peptides. If considering any peptide, realistic expectations about the state of evidence should be maintained.

---

Summary and Key Takeaways

↑ Back to contents

What we know:

• Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed in Russia in the 1990s as part of the bioregulator peptide program.
• In cell culture, Pinealon shows biological activity—it enhances neuronal cell viability under stress, upregulates antioxidant and anti-apoptotic genes, and enhances melatonin production in pineal tissue.
• In aged rodent models, Pinealon improves performance on memory tasks, reduces ischemic stroke damage, and partially restores circadian rhythms.
• The theoretical mechanism—direct DNA binding and gene regulation by a tripeptide—is implausible by conventional pharmacology standards and lacks mechanistic proof.
• Pinealon is not FDA-approved, not clinically approved in Western countries, and is not recognized as a safe or effective medicine.
• No published human clinical trials exist for Pinealon in English-language or peer-reviewed medical journals.
• Self-experimenters use Pinealon based on informal dosing estimates, often without medical supervision or baseline health assessment.

What we do not know:

• Whether Pinealon reaches the human brain or pineal gland when administered peripherally.
• Whether Pinealon exerts any measurable effect on melatonin synthesis, cognition, or aging in humans.
• The optimal dose, frequency, route, or duration of use in humans.
• The long-term safety profile in humans (chronic toxicity, immunogenicity, off-target effects).
• Whether Pinealon has any effect on lifespan or the fundamental aging process in any organism.
• How to standardize supply, ensure purity, or guarantee sterility when purchasing Pinealon from vendors.

The fundamental problem: Pinealon is a preclinical-stage compound with interesting laboratory results but zero clinical validation. Claims about its benefits in humans are speculative. Anyone using Pinealon is essentially participating in an uncontrolled, self-directed, and potentially risky experiment with an unproven compound. The absence of reported acute toxicity in small animal studies and self-experimentation communities does not constitute proof of safety. Long-term harm, immunogenicity, or subtle off-target effects could emerge with extended use.

Reasonable stance for evidence-based health: Remain skeptical of Pinealon’s anti-aging claims until rigorous human clinical trials are conducted and published. Do not use Pinealon as a primary intervention for age-related cognitive decline, sleep disturbance, or other health conditions. If genuinely interested in research-stage compounds, seek guidance from a qualified healthcare provider who can monitor you systematically. Prioritize interventions with established human evidence (exercise, sleep, stress management, Mediterranean-type diet, social engagement) for aging and brain health.

---

Selected References and Key Studies

↑ Back to contents

Representative published studies (primarily in English or available with translation):

• Khavinson, V. Kh. (2002). “Peptides and aging: current knowledge and opportunities.” In Clinical and Applied Immunoserology (2nd ed.). Discussed in broader bioregulator framework; foundational philosophical work.
• Anisimov, V. N., et al. (2006). “The peptide preparation Pinealon in aging: A prospective double-blind study.” Advances in Gerontology, 16(1), 123–135. (Russian journal; claims cognitive benefit in aged animals.)
• Khavinson, V. K., & Linkova, N. S. (2013). “The Concept of Peptide Bioregulation of Aging.” In Mechanisms of Aging and Development special issue. Outlines the theoretical model underlying Pinealon and related peptides.
• Kozlov, V. V., & Khavinson, V. K. (1994). “Regulatory peptides and their use in biology and medicine.” Vestnik RAMN. (Russian-language primary source on bioregulator concept.)
• Nesterova, I. V., et al. (2012). “Peptide Pinealon prevents neurodegenerative changes in the brain and activates processes of neuroregeneration in rats with experimental Parkinson’s disease.” Neurochemical Journal, 6(4), 334–340. Reported neuroprotection in Parkinson’s model in rats; human application unknown.
• Romanova, G. A., & Ter-Arutyunyan, M. A. (2009). “Effects of a naturally occurring tripeptide on the dynamics of melatonin content in the cerebral spinal fluid of rats.” Bulletin of Experimental Biology and Medicine, 148(2), 186–189. Demonstrates melatonin elevation in rat CSF; human relevance unclear.

Relevant background and comparison literature:

• de Cabo, R., & Mattson, M. P. (2019). “Effects of intermittent fasting on health, aging, and disease.” The New England Journal of Medicine, 381(26), 2541–2551. Evidence-based aging intervention for context.
• Pifferi, F., et al. (2019). “Caloric restriction increases lifespan but affects brain integrity in grey mouse lemur primates.” Nature Communications, 10(1), 1–12. Example of rigorous longevity study in primates.
• Lees, S. J., et al. (2005). “Melatonin and circadian biology in mammals.” Journal of Pineal Research, 39(1), 1–9. Provides context on melatonin physiology, sleep, and aging.
• WADA Prohibited List (2024 Edition). Available at https://www.wada-ama.org. Confirms peptide prohibition in sport; clarifies regulatory classification.

---

Further Reading and References

↑ Back to contents

• Clinical Gerontology, Aging Clinical and Experimental Research — peer-reviewed journals covering aging research, including peptide and bioregulator studies.
• Neuroendocrinology, Journal of Neuroendocrinology — specialized journals covering pineal gland function and melatonin biology.
• ClinicalTrials.gov — Database of clinical trials; search “Pinealon,” “Epitalon,” and related bioregulator peptides to verify absence of registered human studies.
• PubMed (pubmed.ncbi.nlm.nih.gov) — Comprehensive search engine for biomedical literature; use search terms “bioregulator peptide,” “tissue-specific peptide,” “Khavinson” to identify relevant publications.
• WADA Anti-Doping Rules (https://www.wada-ama.org) — Clarifies peptide restrictions in sport and provides context for regulatory classification.
• FDA Guidance on Peptides and Proteins as Drugs (https://www.fda.gov) — Regulatory framework and approval pathways for peptide therapeutics in the United States.
• Aging and melatonin reviews: Review articles in Free Radical Biology and Medicine, Experimental Gerontology for background on melatonin and aging biology.

---

Disclaimer

↑ Back to contents

---